Kornimate/medical-research-clean huggingface dataset:
effects of acute exercise on pain and human movement

Conditions: Chronic Musculoskeletal Disease; Chronic Pain, Widespread

Summary: the aim of this research project is to evaluate the effect of an acute exercise intervention on pain intensity and movement control. it also aims to investigate potential differences in movement con-trol between patients with chronic musculoskeletal pain compared to healthy controls.

the aim of this research project is to evaluate the effect of an acute exercise intervention on pain intensity and movement control. it also aims to investigate potential differences in movement control between patients with chronic musculoskeletal pain compared to healthy controls. all tests will be conducted at dalarna university. after the initial baseline tests, participants will be randomised to either acute exercise intervention group or to a control group not performing any intervention groups (both patients and controls will be randomised to intervention or control). if randomised to the control group, participants rests corresponding to the time it takes to perform the intervention (30 min), and then preform the post-intervention tests similar as the intervention group.

Eligibility criteria:
inclusion criteria: inclusion criteria for participants with chronic pain: * men and women, age 18-67 years, * good ability to understand written and verbal information and instruction given in swedish, * chronic (\>3 months) musculoskeletal pain or chronic widespread pain. inclusion criteria for healthy controls: * men and women, age 18-67 years, * good ability to understand written and verbal information and instruction given in swedish. exclusion criteria: for participants with chronic pain * chronic pain caused by malignancies or systemic diseases, other physical conditions that affects functional abilities and implies use of walking aid in-door, * pregnancy after week 12, childbirth within the last 3 months or * spinal surgery. for healthy controls: * chronic (\>3 months) or acute pain of any cause, * other physical conditions that affects functional abilities, and implies use of walking aids in-door, * pregnancy after week 12, childbirth in the last 3 months or * spinal surgery.

Keywords: chronic musculoskeletal pain acute exercise movement control muscle activity
dendritic cell vaccination to prevent hepatocellular carcinoma recurrence after liver resection-phase ii clinical trial

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma (hcc) is the most common primary liver tumors. surgical resection remains the first choice of early stage hcc because the result is superior to other treatments and not limited to liver donation. however, liver resection is criticized that tumor recurrent rate is more than 50% in 5 years although the tumors are completely resected. in our large scale study including 1639 patients with liver resection for hcc, the 1-, 3-, and 5-year disease survival were 73.7%, 58.3% and 53.3%, respectively. currently there are no effective treatment used as adjuvant therapy to prevent hcc recurrence. dendritic cells (dc) are the most potent professional antigen-presenting cells, and can capture tumor antigens to provoke antigen-specific cytotoxic t-cells. dc pulsed by tumor associated antigens can be used to proceed tumor-specific immunotherapy. thereafter, dc pulsed hcc tumor-antigens may be used as an adjuvant therapy to prevent hcc recurrence.


Eligibility criteria:
inclusion criteria: * the patients have curative liver resection for primary or recurrent hccs which are diagnosed by pathological figures, and the risk nomogram scores of tumor recurrence are ≥ 101 \[hepatitis, score 57; platelet \ 43.3cm3 ,score 90\] * age ≧20 years old and sign informed consent. * bclc stage a-c * child-pugh sore ≤ 6 * percentage of lymphocytes in peripheral blood ≧12%. * performance status ecog ≦2 * ast and alt ≦ 5x upper limit of normal. * platelet ≥ 80000/mm3 * wbc ≥ 3000/ul * rbc ≥ 2.5x106/ul * egfr ≥ 30ml/min/1.73m2 * the patients must be disease-free after liver resection, which is confirmed by dynamic ct or mri within 14 days. * the participates must have early stage or intermediate stage of hcc and receive liver resections to remove the tumors completely. * the participates must agree to harvest and preserve tumor specimens during operation. exclusion criteria: * subjected having other malignancy except hcc are excluded. * uncontrolled or clinical significant cardiac diseases. * positive for hiv. * active bacterial of fungal infections. * prior chemotherapy within one month. * use of other investigational drug within one month. * subjects with systemic steroid treatment within 14 days. * subjects in the status of immune deficiency. * subjects in the status of autoimmune diseases. * subjects with long-term use of immunosuppressive agents. * subjects with checkpoint inhibitor immunotherapy within one month. * subjects with local reginal therapy within one month.

Keywords: hepatocellular carcinoma recurrence
prospective evaluation of temporomandibular joint pathologies in scoliosis patients with ultrasonography and clinical examination

Conditions: Scoliosis Patients

Summary: from the anatomical and functional point of view, stomatognathic system and spine have close connections. together with the complex neuromuscular relationships, this creates an important area of cooperation between dentists and orthopedics (1). the cause of scoliosis has not been precisely explained, and various causes have been suggested in the literature, such as deviation from the standard growth pattern, neuromuscular tissue changes, asymmetric growth of the trunk, changes in the sagittal configuration of the spine, and environmental factors. in addition, scoliosis may develop secondary to each of hereditary musculoskeletal disorders such as osteogenesis imperfecta, marfan syndrome, stickler syndrome, ehlers-danlos syndrome and muscular dystrophies. fonder et al. conducted case studies showing the relationship between dental occlusion and scoliosis (2). there are studies suggesting that temporomandibular joint (tmj) diseases are observed more frequently with the effect of the head-neck muscle balance affected by scoliosis and the irregularities in the occlusion. at the same time, some studies have shown that patients with mandible changes (deviation, deflection, asymmetry...), which is one of the tmj components, often have abnormal morphology in the cervical vertebrae (3). ito g et al. they reported that body posture is closely related to the function of the head support system. the cervical spine and muscles play an important role in stabilizing the head posture and in the complex and various movements of the head (4). there is no study in the literature comparing the severity of scoliosis and tmj joint dysfunction radiologically and clinically. in this study, tmj of scoliosis patients was evaluated by ultrasonography and clinical examination; it was aimed to correlate the severity of scoliosis with joint dysfunction.


Eligibility criteria:
inclusion criteria: * being between the ages of 12-18 * being diagnosed with adolescent idiopathic scoliosis exclusion criteria: * being diagnosed with neuromuscular, juvenile or congenital scoliosis * having received surgical treatment for scoliosis * rheumatological disease * having received treatment for tmj dysfunction

Keywords: ultrasonography
tq-pal development and validation

Conditions: Altered Taste

Summary: taste problems are common among patients with advanced cancer. these symptoms can affect the pleasure of eating and drinking, reduce dietary intake, cause low mood, and a lower quality of life. there is no validated tool to assess taste disturbances and their impact on patients with advanced cancer. this study will develop and validate a novel assessment tool to assess taste disturbances and their impact on patients with advanced cancer.

patients with advanced cancer often develop taste disturbances. a recent literature review reported a median prevalence of 55%, with prevalence ranging from 27-93%. studies have shown taste disturbance is usually a persistent symptom, is often 'moderate-to-severe' in intensity, and is often associated with significant distress. taste disturbance may have a major impact on the experience and pleasure associated with eating and drinking. taste disturbance may have a major impact on nutritional intake. it may be associated with low mood / depression, social isolation, and an impaired quality of life. the aforementioned literature review identified, importantly, that the terminology used in the published literature varied, which may have had an effect on the results obtained, especially prevalence statistics. the review identified the need for "development/validation studies of a taste-specific assessment tool for this group of patients - there is a need for a tool that not only assesses the problem but can also assess the response to treatment for the problem, utilising patient reported outcome measures."

Eligibility criteria:
inclusion criteria: 18 years of age diagnosis of locally advanced or metastatic cancer referred to palliative care/oncology services taste problems rated 'moderate' or worse over previous 2-week period good understanding of english exclusion criteria: cognitive impairment (unable to provide consent / complete questionnaire) taste problems precedes cancer diagnosis. head and neck surgery head and neck radiotherapy salivary gland disorders (e.g., sjogren's syndrome) in the 'deteriorating' or 'terminal' phase of illness

Keywords: neoplasm
reversal of cognitive decline (recode) study

Conditions: Alzheimer Disease; Mild Cognitive Impairment

Summary: prospective study on patients enrolled in the recode treatment protocol

the objective of the study is to determine if the recode treatment has a measurable impact on the typical progression of neurocognitive decline observed in patients with alzheimer's disease (ad) and patients who are exhibiting mild cognitive impairment (mci). mci is often a precursor to an ad diagnosis. for this study, there will be no distinction made between participants who have been diagnosed with ad and those who show signs of mci.

Eligibility criteria:
inclusion criteria: * 45 to 76 years old * adults of any gender, race or ethnicity * subjects must have cognitive impairment as demonstrated by a combination of aq-21 over 5 and either a moca 26 or below or a cns vitals screening assessment in the mci in the bottom 70th percentile or 2 of the subtests in the bottom 50th percentile. * proficient in spoken and written english for consenting as well as for study participation. * must be able to use a computer and web interface. if assistance is needed, it must be readily available to them. * regular access to a computer and an internet connection since certain aspects of the program (e.g. cognitive training) are delivered electronically * willing and able to follow the protocol if the treating physician determines that is required for appropriate patient care. exclusion criteria: * uncontrolled major medical illness, seizures, cardiovascular or cerebrovascular instability. * a major psychiatric diagnosis that affects activities of daily living (adl) or functioning. * currently taking psychoactive medications known to impact cognition. * use of statin therapy, unless eligible to discontinue. * use of anticoagulation therapy or history of deep vein thrombosis. * mri findings of hydrocephalus, focal stroke, extensive white matter disease or brain tumor. * experienced traumatic brain injury (tbi) that is severe enough that it has an ongoing impact on patient function on a regular basis. * lack of support (either family member or caregiver) to assist with following the treatment protocol. * active cancer, cancer within the past five years or any history of breast cancer. * inability to exercise. * inability to use a computer, or no computer access. * unwillingness or ineligibility to use bioidentical hormone replacement. * pregnancy or any chance of becoming pregnant during the course of the study period. * presence of an existing diagnosis of a non-ad neurodegenerative disorder (e.g., lewy body disease, frontotemporal disease, chronic traumatic encephalopathy, korsakoff's syndrome). * diagnosis of cerebrovascular disease as the primary cause of cognitive impairment. * previous treatment or experience with recode.

Keywords: dementia alzheimer's disease cognitive decline mci
culturally sensitive cognitive behavioural therapy for the survivors of intimate partner violence (ipv)

Conditions: Mental Abuse of Adult; Emotional Abuse; Domestic Violence

Summary: women experience negative psychological outcomes long after the violent relationship has ended. women suffer constant trauma and psychological distress being in emotional and mentally abusive relationship. present study developed culturally sensitive cognitive-behaviour therapy (cbt) to fit the client's cultural identity, context, and preferences.


Eligibility criteria:
inclusion criteria: * women victim of intimate partner violence * still in relationship with abuser * willing to attend 16-weeks sessions exclusion criteria: * in need of clinical supervision or treatment * severe mental disorders * cognitive disorders * refused to give written consent
thoracic mobilization for restrictive lung disease

Conditions: Restrictive Lung Disease

Summary: this study aims to investigate the immediate effects of thoracic mobilization techniques on cough capacity, dyspnea, and pulmonary function in patients with restrictive lung disease. the intervention will be applied in a single session, and outcomes will be measured before and after the intervention to evaluate short-term physiological changes.

restrictive lung disease (rld) is characterized by reduced lung compliance and limited thoracic mobility, leading to decreased lung volume and impaired respiratory function. manual therapy interventions such as thoracic mobilization have been proposed to improve chest wall flexibility and enhance respiratory efficiency. however, few studies have examined the immediate clinical effects of such interventions in rld patients. this single-group pre-post interventional study will evaluate the short-term outcomes of thoracic mobilization techniques on cough capacity (as measured by peak cough flow), dyspnea (via borg scale), and pulmonary function (forced vital capacity \[fvc\], forced expiratory volume in 1 second \[fev1\]). the results are expected to provide preliminary evidence on the effectiveness of thoracic mobilization for improving respiratory performance in individuals with rld.

Eligibility criteria:
inclusion criteria: * age 19 years or older * currently receiving respiratory therapy at c hospital in sejong city * pulmonary function test indicating restrictive pattern: fvc \< 80% and fev1/fvc ≥ 70% * fvc above the lower limit of normal (lln) for age and sex * diagnosed with restrictive lung disease, such as idiopathic pulmonary fibrosis, scoliosis, or neuromuscular disorders (e.g., myopathy, amyotrophic lateral sclerosis) exclusion criteria: * fev1/fvc ratio \< 70% * evidence of airway obstruction on pulmonary function testing

Keywords: thoracic mobilization pulmonary function cough capacity dyspnea restrictive pulmonary disorder
empower - bame vs covid

Conditions: COVID-19, SARS-CoV 2 Infection; Health Disparities

Summary: the covid-19 virus pandemic has massively affected us all. moreover, there is a disproportionately high number of covid-19 severe infections and deaths in british black, asian and minority ethnic (bame) patients. this clinical study plans to discover new ways of protecting people from this virus by looking at our dna and biology.

the covid-19 virus pandemic has massively affected us all. we now know there is a much larger proportion of british black, asian and minority ethnic (bame) patients suffering from covid-19 infections. this disproportionate level of infection and severity of disease has raised concerns and worries. other research from april 2020 showed that 71% of the nurses and midwives and 94% of the doctors and dentists that died of covid-19 infections were from a bame background despite this group representing 20% and 44% of the workforce respectively. the survival picture is also grim for black and asian members of the public where we see disproportionately high rates of deaths. research estimates that our dna and the environment equally influence the risk for infection. this clinical study plans to better understand our dna. some of the things we will be looking at is age, sex, ethnicity and any illnesses such as diabetes or blood pressure. we will ask people for some spit and look at their medical records. this may help us find some of the reasons why this virus has different effects on people and how we might protect people from covid-19.

Eligibility criteria:
inclusion criteria: 1. all competent adult and children above the age of 5 years 2. subjects agree to: 1. gift saliva (spit) samples 2. provide consent for access to medical and health records exclusion criteria: 1. patient is not registered with the nhs for care. 2. adults lacking capacity 3. children under the age of 6 years.

Keywords: ethnic minority, health disparity, epidemiology, biomarker discovery, public health, bame, morbidity, mortality, covid-19, sars-cov-2
tow techniques of adductor canal block for analgesia after total knee replacement

Conditions: Total Knee Arthroplasty; Analgesia; Nerve Block

Summary: this study compares the tow technique of continues adductor canal block for total knee replacement surgery. half participants will receive catheterization at the entrance of the adductor canal, while the other half will receive catheterization at the middle point of the adductor canal.


Eligibility criteria:
inclusion criteria: * 18-80 years * knee-arthroscopy * written consent * asa i-iii * bmi 19-35 exclusion criteria: * unable to communicate with the investigators (e.g., a language barrier or a neuropsychiatric disorder). * coagulopathy or on anticoagulant medication * allergic reactions toward drugs used in the trial * history of substance abuse * infection at injection site * can not be mobilised to 5 meters of walk pre-surgery

Keywords: adductor canal block
somatuline autogel preference and health economy study

Conditions: Neuroendocrine Tumour With Carcinoid Symptoms

Summary: the primary aim of this study is to assess which method of lanreotide autogel administration patients with neuroendocrine tumours prefer - self/partner administrations or healthcare provided administrations. the study will also assess if self/partner administration can be performed without loss of efficacy and with a preserved safety profile. the impact of self/partner administration on resource utilisation and costs will be studied. in addition, we will also assess the healthcare provider's experience of the two administration practices.


Eligibility criteria:
inclusion criteria: * provision of written informed consent from the patient and their partner (if the partner will be administering the lanreotide autogel injections during the self administration period) * male or female aged 18 years of age or older * treated with lanreotide autogel 90 or 120 mg every 28th day for carcinoid symptoms on a stable dose for at least 3 months prior to inclusion. the patient is presumed to be clinically stable during the coming months * neuroendocrine tumour confirmed by biopsy and visible on radiology exclusion criteria: * has a history of hypersensitivity to the investigational medicinal product or drugs with a similar chemical structure * has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might jeopardise the patient's safety or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study * has a life expectancy less than a year, as judged by the investigator * the patient or their partner is not considered competent in injection technique, as judged by the investigator
a study assessing saxagliptin treatment in type 2 diabetic subjects who are not controlled with tzd therapy alone

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this clinical research study is to learn whether saxagliptin added to thiazolidinedione (tzd) therapy is more effective than tzd alone as a treatment for type 2 diabetic subjects who are not sufficiently controlled with tzd alone

all subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. subjects who complete the short-term period will be eligible to enter the long term extension period. also, subjects in the short-term period who have an elevated blood sugar that requires additional medication for blood sugar control will be eligible to enter the long-term treatment extension period where they will receive metformin (defined as rescue medication) added onto their blinded study medication

Eligibility criteria:
inclusion criteria: * type 2 diabetics currently receiving a stable dose of tzd monotherapy (pioglitazone 30mg or 45mg, or rosiglitazone 4mg or 8mg) for at least 12 weeks prior to screening. * hemoglobin a1c (hba1c) \> = 7.0% and \< = 10.5% * body mass index \< = 45kg/m2 * fasting c-peptide \> = 1 ng/ml exclusion criteria: * symptomatic poorly controlled diabetes * recent cardiac or cerebrovascular event * serum creatinine \> = 2.0 mg/dl